Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.60 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.60 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CD69 | Q07108 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24699873 | 1.00 | MAPK1 (0.76) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL26075521 | 1.00 | MAPK1 (0.76) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL22855478 | 1.00 | MAPK1 (0.76) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL24015418 | 1.00 | MAPK1 (0.76) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL26075450 | 1.00 | MAPK1 (0.76) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL22830100 | 0.99 | MAPK1 (0.74) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL17932962 | 0.95 | MAPK1 (0.80) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL25480938 | 0.95 | MAPK1 (0.80) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL8104766 | 0.95 | MAPK1 (0.80) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL22927889 | 0.95 | MAPK1 (0.80) | MAPK1LGALS8LGALS3LGALS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0970114-B1 | NEOGLYCOPROTEINS | NOVARTIS AG (CH) | 2006-07-12 | — | — | EP | disclosed |
| US-6723831-B2 | REMOVAL ANTIBODIES FROM BODY FLUIDS | NOVARTIS AG (CH) | 2004-04-20 | — | — | US | disclosed |
| US-20020164347-A1 | Neoglycoproteins | DUTHALER RUDOLF (CH) | 2002-11-07 | — | — | US | disclosed |
| US-6399071-B1 | Neoglycoproteins | NOVARTIS AG (CH) | 2002-06-04 | — | — | US | disclosed |
| EP-0970114-A1 | NEOGLYCOPROTEINS | Novartis AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998047915-A1 | NEOGLYCOPROTEINS | NOVARTIS AG (CH) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020164347-A1 | Neoglycoproteins | CD68, DNPEP, LNPEP | MAPK1 4520/4885LGALS8 70/4885LGALS3 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.